Wechselwirkungen · Revatio
Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 25–26
HOS-114985 · Präparat HOS-094193
25 Effects of other medicinal products on intravenous sildenafil Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A4 inhibitors should be less than observed after oral sildenafil administration. The magnitude of the interaction is expected to be reduced for intravenous sildenafil, as interactions for oral sildenafil are due, at least in part, to effects on oral first pass metabolism.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage d5fc75254b5ef87b8e82db9bbac3ac398d180cc0ce6a3563e88a4c808d552771 · Zeichen 260–688 im Abschnitt